Tag:
Acambis
Latest Headlines
Latest Headlines
Pharma turns to small developers for vax tech
Paul Bogorad at Putnam Associates is bullish about the vaccine business. Reviewing the now familiar story line about Big Pharma's embrace of vaccines after years of neglect, Mass High Tech relates
Acambis plots post-buyout expansion
Wayne Pisano, who runs Sanofi-Aventis's vaccine arm, says that the newly acquired Acambis will be kept at arm's length with a minimum of bureaucratic controls to slow it down. But Pisano also
Sanofi closes deal on Acambis
Sanofi-Aventis closes on its deal to buy Acambis today, but it's working hard to avoid losing the entrepreneurial spirit that attracted the French pharma company to the vaccine developer in the first
Acambis plots growth after $549M buyout
Sanofi-Aventis' announcement earlier this week that it is buying the UK's Acambis for $549 million is fresh evidence of a buoyant vaccine market. The French drug company is paying a 65 percent
Acambis shares soar on $548M buyout deal
Shares of Acambis PLC soared after Sanofi-Aventis announced that it planned to buy the vaccine developer for $548 million. Aside from the smallpox vaccine ACAM2000, which recently won a 10-year, $425
Sanofi makes $548M deal for Acambis
Sanofi Pasteur has inked a deal to buy vaccine-maker Acambis for about $548 million (£276 million), a 64 percent per-share premium. The two companies had already been working together on a
Sanofi to acquire Acambis for $546M
More evidence that the vaccine market is hot: vaccine maker Acambis has agreed to a £276 million ($546 million) by Sanofi-Pasteur, the vaccines division of France's Sanofi-Aventis. The deal
SPOTLIGHT: Acambis contract offers long-term funding
The announcement that Acambis has won a $425 million, 10-year contract to supply the U.S. government with its smallpox vaccine, along with a new share placement, will provide the company with enough
Acambis lands $425M smallpox vaccine contract
The U.K.'s Acambis has won a $425 million contract to supply the CDC with its smallpox vaccine for 10 years. Acambis will establish a U.S.-based manufacturing capability for ACAM2000 and deliver a
Out with old, in with new smallpox vaccine
With a new smallpox vaccine accumulating in federal stockpiles, the U.S. government is disposing of millions of doses of Dryvax, the old smallpox vaccine that relies on skin scrapings from infected
